

(Print or Type Responses)

1. Name and Address of Reporting Person * BHONSLE SUNIL		2. Issuer Name and Ticker or Trading Symbol TITAN PHARMACEUTICALS INC [TTP]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <div><div><input checked="" type="checkbox"/> Director</div><div><input type="checkbox"/> 10% Owner</div><div><input checked="" type="checkbox"/> Officer (give title below)</div><div><input type="checkbox"/> Other (specify below)</div></div> <div>EVP &amp; COO</div>					
(Last) (First) (Middle) C/O TITAN PHARMACEUTICALS INC, 400 OYSTER POINT BLVD		3. Date of Earliest Transaction (Month/Day/Year) 11/03/2005							
(Street) S SAN FRANCISCO, CA 94080		4. If Amendment, Date Original Filed(Month/Day/Year) 11/07/2005		6. Individual or Joint/Group Filing (Check Applicable Line) <div><div><input checked="" type="checkbox"/> Form filed by One Reporting Person</div><div><input type="checkbox"/> Form filed by More than One Reporting Person</div></div>					
(City) (State) (Zip)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price		
COMMON STOCK	11/03/2005		P		9,900	A	\$ 1.52	29,400 (1)	D
COMMON STOCK								60,894 (2)	I  AS TRUSTEE OF A FAMILY TRUST

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BHONSLE SUNIL C/O TITAN PHARMACEUTICALS INC 400 OYSTER POINT BLVD S SAN FRANCISCO, CA 94080	X		EVP & COO	

## Signatures

/s/		11/09/2005
**Signature of Reporting Person		Date

Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The original Form 4 mistakenly reported that the reporting person beneficially owned 90,294 shares of common stock directly and 100,000 indirectly. This Form is being filed with the correct amounts.
- (2) Does not include 10,000 shares of common stock beneficially owned by the reporting person's adult son.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.